Fenwick represented Endpoint Health, Inc., a precision-first™ therapeutics company dedicated to addressing urgent needs in immune-driven critical and chronic illnesses, in a global collaboration and licensing agreement with Grifols (NASDAQ: GRFS), a leading global producer of plasma-derived medicines.
Under the terms of the agreement, Grifols will provide up to $25 million to support the clinical development of Antithrombin III in sepsis. Endpoint Health plans to submit its Investigational New Drug (IND) Application and Investigational Device Exemption (IDE) to the U.S. Food and Drug Administration (FDA) later this year for a Phase II clinical trial of Antithrombin III. More information about the collaboration can be obtained from Endpoint Health’s announcement.
The Fenwick team included life sciences partner Key Shin and associate Zach Harned, and corporate partner Matt Rossiter.